Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
BACKGROUND: A single infusion of intravenous zoledronic acid decreases bone turnover and improves bone density at 12 months in postmenopausal women with osteoporosis. We assessed the effects of annual infusions of zoledronic acid on fracture risk during a 3-year period. METHODS: In this double-blind, placebo-controlled trial, 3889 patients (mean age, 73 years) were randomly assigned to receive a single 15-minute infusion of zoledronic acid (5 mg) and 3876 were assigned to receive placebo at baseline, at 12 months, and at 24 months; the patients were followed until 36 months. Primary end points were new vertebral fracture (in patients not taking concomitant osteoporosis medications) and hip fracture (in all patients). Secondary end points included bone mineral density, bone turnover markers, and safety outcomes. RESULTS: Treatment with zoledronic acid reduced the risk of morphometric vertebral fracture by 70% during a 3-year period, as compared with placebo (3.3% in the zoledronic-acid group vs. 10.9% in the placebo group; relative risk, 0.30; 95% confidence interval [CI], 0.24 to 0.38) and reduced the risk of hip fracture by 41% (1.4% in the zoledronic-acid group vs. 2.5% in the placebo group; hazard ratio, 0.59; 95% CI, 0.42 to 0.83). Nonvertebral fractures, clinical fractures, and clinical vertebral fractures were reduced by 25%, 33%, and 77%, respectively (P<0.001 for all comparisons). Zoledronic acid was also associated with a significant improvement in bone mineral density and bone metabolism markers. Adverse events, including change in renal function, were similar in the two study groups. However, serious atrial fibrillation occurred more frequently in the zoledronic acid group (in 50 vs. 20 patients, P<0.001). CONCLUSIONS: A once-yearly infusion of zoledronic acid during a 3-year period significantly reduced the risk of vertebral, hip, and other fractures. (ClinicalTrials.gov number, NCT00049829.)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Zoledronic acid reduces the incidence of vertebral fractures by 70 % (with significant reduction at 1 year), hip fractures by 41 %, and nonvertebral fractures by 25 % over 3 years in patients with osteoporosis defined by prevalent vertebral fractures and osteoporosis by BMD of the hip [66].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [66]
In the citing paper
“There is abundant evidence that the elevated risk of fracture in patients with osteoporosis by BMD is reduced with pharmacotherapy [52, 57, 59–70].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [66]
In the citing paper
“Zoledronic acid reduces the incidence of vertebral fractures by 70 % (with significant reduction at 1 year), hip fractures by 41 %, and nonvertebral fractures by 25 % over 3 years in patients with osteoporosis defined by prevalent vertebral fractures and osteoporosis by BMD of the hip [66].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [66]
In the citing paper
“Zoledronic acid reduces the incidence of vertebral fractures by 70 % (with significant reduction at 1 year), hip fractures by 41 %, and nonvertebral fractures by 25 % over 3 years in patients with osteoporosis defined by prevalent vertebral fractures and osteoporosis by BMD of the hip [66].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [66]
Citations
Cites
Black, D. M., Cummings, S. R., Karpf, D. B., Cauley, J. A., Thompson, D. E., Nevitt, M. C., Bauer, D. C., Genant, H. K., Haskell, W. L., Marcus, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07088-2 · Cited by 3,846
Self-citationVertebral fracture assessment using a semiquantitative technique
Genant, H. K., Wu, C. Y., van Kuijk, C., & Nevitt, M. C. (1993) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650080915 · Cited by 3,691
Cummings, S. R. (1998) · JAMA · doi:10.1001/jama.280.24.2077 · Cited by 2,277
Self-citationOsteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases
Ruggiero, S. L., Mehrotra, B., Rosenberg, T. J., & Engroff, S. L. (2004) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2004.02.004 · Cited by 2,057
Effect of Risedronate on the Risk of Hip Fracture in Elderly Women
McClung, M. R., Geusens, P., Miller, P. D., Zippel, H., Bensen, W. G., Roux, C., Adami, S., Fogelman, I., Diamond, T., Eastell, R., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200102013440503 · Cited by 1,918
Self-citationReginster, J.-Y., Minne, H. W., Sorensen, O. H., Hooper, M., Roux, C., Brandi, M. L., Lund, B., Ethgen, D., Pack, S., Roumagnac, I., et al. (2000) · Osteoporosis International · doi:10.1007/s001980050010 · Cited by 1,580
Self-citationSystematic Review: Bisphosphonates and Osteonecrosis of the Jaws
Woo, S.-B., Hellstein, J. W., & Kalmar, J. R. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-144-10-200605160-00009 · Cited by 1,252
Chesnut, C. H., Skag, A., Christiansen, C., Recker, R., Stakkestad, J. A., Hoiseth, A., Felsenberg, D., Huss, H., Gilbride, J., Schimmer, R. C., et al. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040325 · Cited by 1,229
Self-citation
Cited by
Items 801–900 of 1,004
Samakkarnthai, P., Saul, D., Zhang, L., Aversa, Z., Doolittle, M. L., Sfeir, J. G., Kaur, J., Atkinson, E. J., Edwards, J. R., Russell, G. G., et al. (2023) · Aging · doi:10.18632/aging.204701 · Cited by 34
“Treatment with zoledronic acid reduces bone turnover, improves bone mineral density (BMD), and reduces fracture risk by as much as 70% [23].”
Liu, J., Lin, X., Sun, L., Zhang, Q., Jiang, Y., Wang, O., Xing, X., Xia, W., & Li, M. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad732 · Cited by 37
Recent Advances in Osteoporosis Therapeutics
Sølling, A. S., Langdahl, B. L., & Cosman, F. (2025) · Annual Review of Medicine · doi:10.1146/annurev-med-050124-040555 · Cited by 49
Self-citationDrug and Gene Delivery using Sonoporation for Cardiovascular Disease
Castle, J. W., & Feinstein, S. B. (2015) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-22536-4_18 · Cited by 35
Teriparatide and the risk of nonvertebral fractures in women with postmenopausal osteoporosis
Krege, J. H., & Wan, X. (2011) · Bone · doi:10.1016/j.bone.2011.10.018 · Cited by 36
“Some trials have included traumatic fractures in the nonvertebral fracture endpoint, while others have excluded traumatic fractures [8,10–13].”
BackgroundEffect of Bisphosphonates on the Rapidly Growing Male Murine Skeleton
Zhu, E. D., Louis, L. D., Brooks, D. J., Bouxsein, M., & Demay, M. B. (2014) · Endocrinology · doi:10.1210/en.2013-1993 · Cited by 39
Giusti, A. (2014) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-014-0584-8 · Cited by 36
“[35].”
BackgroundMethodInfluentialEdwards, W. B., Simonian, N., Troy, K. L., & Schnitzer, T. J. (2015) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2474 · Cited by 37
Vestergaard, P., Schwartz, K., Pinholt, E. M., Rejnmark, L., & Mosekilde, L. (2010) · Calcified Tissue International · doi:10.1007/s00223-010-9349-0 · Cited by 35
“Intravenous treatment with zoledronic acid has been associated with an excess risk of atrial fibrillation compared to placebo in randomized controlled trials [1].”
BackgroundInfluentialSite specific measurements of bone formation using [18F] sodium fluoride PET/CT
Blake, G. M., Puri, T., Siddique, M. M., Frost, M. L., Moore, A. E. B., & Fogelman, I. (2018) · Quantitative Imaging in Medicine and Surgery · doi:10.21037/qims.2018.01.02 · Cited by 35
Anabolic and antiresorptive actions of locally delivered bisphosphonates for bone repair
Qayoom, I., Raina, D. B., Širka, A., Tarasevičius, Š., Tägil, M., Kumar, A., & Lidgren, L. (2018) · Bone and Joint Research · doi:10.1302/2046-3758.710.bjr-2018-0015.r2 · Cited by 34
Kang, M.-H., Lee, D.-K., Kim, C.-W., Song, I., & Jun, S.-H. (2018) · 대한구강악안면외과학회지 · doi:10.5125/jkaoms.2018.44.5.225 · Cited by 34
Robinson, W. A., Carlson, B. C., Poppendeck, H., Wanderman, N., Bunta, A. D., Murphy, S. A., Sietsema, D. L., Daffner, S. D., Edwards, B. J.-A., Watts, N. B., et al. (2019) · Spine · doi:10.1097/brs.0000000000003324 · Cited by 36
Therapeutic Dimensions of Bisphosphonates: A Clinical Update
Vannala, V., Palaian, S., & Shankar, P. R. (2020) · International Journal of Preventive Medicine · doi:10.4103/ijpvm.ijpvm_33_19 · Cited by 39
“[50] 1.c. Zolendronate Atrial fibrillation is one of the adverse effects that is more evident in postmenopausal osteoporotic women receiving zoledronate through the IV route; this was ruled out on the long‑term administration of zolendronate in HORIZON Pivotal Fracture Trial.”
BackgroundGrey, A. B., Bolland, M. J., Horne, A. M., Mihov, B., Gamble, G. D., & Reid, I. R. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4453 · Cited by 34
“Introduction The intravenous bisphosphonate zoledronate reduces fracture risk in older adults.((1-3)) It has prolonged activity in bone, such that administration as infrequently as every 18 months prevents fractures,((3)) and administration every 2 years is approved for prevention of bone loss.”
BackgroundSelf-citationZoledronic acid and clinical fractures and mortality after hip fracture
Elmans, L. H. G. J. (2008) · Nederlands Tijdschrift voor Traumatologie · doi:10.1007/bf03077197 · Cited by 34
Risks and benefits of long-term bisphosphonate therapy
Schmidt, G. A., Horner, K. E., McDanel, D. L., Ross, M. B., & Moores, K. G. (2010) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp090506 · Cited by 39
Ko, S. S., & Jordan, V. C. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.557360 · Cited by 38
“For hip fracture prevention, the evidence for zoledronic acid is again fair [79,80].”
RetractedCatalano, A., Morabito, N., Atteritano, M., Basile, G., Cucinotta, D., & Lasco, A. (2012) · Calcified Tissue International · doi:10.1007/s00223-012-9577-6 · Cited by 58
Secondary Causes of Osteoporosis in Fracture Patients
Bogoch, E. R., Elliot-Gibson, V. I. M., Wang, R. Y. C., & Josse, R. G. (2012) · Journal of Orthopaedic Trauma · doi:10.1097/bot.0b013e3182323f2c · Cited by 36
Carvas, J. S. B., Pereira, R. M. R., Caparbo, V. F., Fuller, P., Silveira, C. A., de Lima, L. A. P. A., Bonfá, E., & de Mello, S. B. V. (2009) · Osteoporosis International · doi:10.1007/s00198-009-1125-5 · Cited by 34
Oswald, A. J., Berg, J., Milne, G., & Ralston, S. H. (2013) · Calcified Tissue International · doi:10.1007/s00223-013-9788-5 · Cited by 35
Hd, N., Em, H., Chou, R., Dana, T., Fu, R., & Bougatsos, C. (2010) · Europe PMC (PubMed Central) · Cited by 45
The effect of osteoporosis treatments on fatigue properties of cortical bone tissue
Brock, G. R., Chen, J. T., Ingraffea, A. R., MacLeay, J., Pluhar, G. E., Boskey, A. L., & van der Meulen, M. C. H. (2015) · Bone Reports · doi:10.1016/j.bonr.2014.10.004 · Cited by 33
“Alendronate was administered daily via cannula while zoledronate was given once over the course of the experiment via intravenous injection following clinical dosing regimens (Bone et al., 2000; Black et al., 2007).”
BackgroundMethodKobayashi, T., Morimoto, T., Ito, K., Mawatari, M., & Shimazaki, T. (2024) · Osteoporosis International · doi:10.1007/s00198-024-07118-0 · Cited by 35
“However, in contrast to our findings, previous studies have found that parenteral administration of bisphosphonates (i.e., zoledronic acid) were associated with a higher risk of incident atrial fibrillation in comparison to denosumab or placebo [86–88].”
Safety concerns with the long-term management of osteoporosis
Reginster, J., Pelousse, F., & Bruyère, O. (2013) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2013.793669 · Cited by 34
Quantitative Radionuclide Studies of Bone
Blake, G. M., Frost, M. L., & Fogelman, I. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.109.063263 · Cited by 33
Roux, C., Reid, D. M., Devogelaer, J. P., Saag, K. G., Lau, C. S., Reginster, J.-Y., Papanastasiou, P., Bucci-Rechtweg, C. M., Su, G., & Sambrook, P. N. (2011) · Osteoporosis International · doi:10.1007/s00198-011-1800-1 · Cited by 35
Brandi, M. L. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.696610 · Cited by 37
Study of Adverse Effect Profile of Parenteral Zoledronic Acid in Female Patients with Osteoporosis
Kotian, P., Boloor, A., & Sreenivasan, S. (2016) · JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH · doi:10.7860/jcdr/2016/17061.7021 · Cited by 35
Investigational Pharmacological Treatments for Vascular Calcification
Schantl, A. E., Ivarsson, M. E., & Leroux, J. (2018) · Advanced Therapeutics · doi:10.1002/adtp.201800094 · Cited by 37
Pharmacogenomics of osteonecrosis of the jaw
Yang, G., Singh, S., Chen, Y., Hamadeh, I. S., Langaee, T. Y., McDonough, C. W., Holliday, L. S., Lamba, J. K., Moreb, J. S., Katz, J., et al. (2019) · Bone · doi:10.1016/j.bone.2019.04.010 · Cited by 39
Qiang, G., Zhang, C., Wang, J., Wei, Q., Wei, Q., Miyamoto, A., Zhu, S., & He, C. (2020) · Archives of Osteoporosis · doi:10.1007/s11657-020-0705-z · Cited by 39
Jackson, C. H., Freeman, A. L. J., Szlamka, Z., & Spiegelhalter, D. J. (2021) · PLoS ONE · doi:10.1371/journal.pone.0246441 · Cited by 38
Westin, J. R., Thompson, M. A., Cataldo, V. D., Fayad, L., Fowler, N. H., Fanale, M. A., Neelapu, S., Samaniego, F., Romaguera, J. E., Shah, J. J., et al. (2012) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2012.11.002 · Cited by 36
Henriksen, K., Leeming, D. J., Christiansen, C., & Karsdal, M. A. (2011) · Women s Health · doi:10.2217/whe.11.74 · Cited by 34
“Zoledronate -58 -59 [59]”
BackgroundNanotechnology Treatment Options for Osteoporosis and Its Corresponding Consequences
Wei, D., Jung, J., Yang, H., Stout, D., & Yang, L. (2016) · Current Osteoporosis Reports · doi:10.1007/s11914-016-0324-1 · Cited by 34
SEIOMM Working Group, Guañabens, N., Moro-Álvarez, M. J., Casado, E., Blanch‐Rubió, J., Gómez‐Alonso, C., Diaz‐Guerra, G. M., del Pino‐Montes, J., Valero, C., Peris, P., et al. (2019) · Endocrine · doi:10.1007/s12020-019-01919-8 · Cited by 34
Biochemical Markers of Bone Metabolism
Cremers, S., Garnero, P., & Seibel, M. J. (2008) · Elsevier eBooks · doi:10.1016/b978-0-12-373884-4.00020-3 · Cited by 57
Cosman, F. (2009) · Endocrine Practice · doi:10.4158/ep08306.orr1 · Cited by 36
Self-citationLi, J.-Z., Fu, S., Yang, Y., An, R., Liu, H.-Y., & Mao, H. (2022) · Climacteric · doi:10.1080/13697137.2022.2102894 · Cited by 35
“This can cause adverse gastrointestinal reactions, and rapid intravenous administration can cause nephrotoxicity [32].”
BackgroundOrozco, C., & Maalouf, N. M. (2012) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2012.09.001 · Cited by 37
“Serious atrial fibrillation (Afib) emerged in 2007 as an unexpected but significant side effect of ZA in the phase 3, double-blind, placebo-controlled clinical trial that showed the efficacy of ZA in reducing osteoporotic fractures in postmenopausal women.(8) In this multicenter trial conducted in 3889 women, serious…”
BackgroundInfluentialThe effects of intravenous zoledronic acid in Chinese women with postmenopausal osteoporosis
Hwang, J., Chin, L.-S., Chen, J., Yang, T., Chen, P.-Q., Tsai, K., & Leung, P. (2010) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-010-0223-y · Cited by 31
Self-citationBisphosphonate Drug Holiday: Choosing Appropriate Candidates
Ro, C., & Cooper, O. B. (2013) · Current Osteoporosis Reports · doi:10.1007/s11914-012-0129-9 · Cited by 33
“The Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly (HORIZON) study raised concern regarding atrial fibrillation when the investigators noted a higher incidence of arrhythmias in the study group than in the placebo group [15].”
BackgroundBisphophonates in CKD Patients with Low Bone Mineral Density
Liu, W.-C., Yen, J.-F., Lang, C.-L., Yan, M.-T., & Lu, K. (2013) · The Scientific World JOURNAL · doi:10.1155/2013/837573 · Cited by 34
“eGFR to 30mL/min benefit from oral or intravenous bisphosphonates for osteoporosis [8, 9], but the use of bisphosphonates inCKD requires some caution.”
BackgroundOsteoporosis treatment: Focus on safety
Reid, I. R. (2013) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2013.03.012 · Cited by 32
“In one of the two zoledronate phase 3 studies, there was an increased incidence of atrial fibrillation reported as a serious adverse event [38,39].”
BackgroundSelf-citationAn observational study of musculoskeletal pain among patients receiving bisphosphonate therapy.
Caplan, L., Pittman, C. B., Zeringue, A., Scherrer, J. F., Wehmeier, K., Cunningham, F., Eisen, S., & Mcdonald, J. (2010) · Mayo Clinic proceedings · doi:10.4065/mcp.2009.0492 · Cited by 32
“The most convincing prior evidence linking bisphosphonates with incident MSKP occurred in the setting of randomized controlled trials with parenteral bisphosphonate formulations.(11,12) However, oral formulations accounted for the vast majority of the bisphosphonates in our study.”
BackgroundLong-term treatment strategies for postmenopausal osteoporosis
Cosman, F. (2018) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000509 · Cited by 35
Self-citationLaboratory aspects and clinical utility of bone turnover markers.
Bhattoa, H. P. (2018) · PubMed Central · Cited by 52
Behanová, M., Reichardt, B., Stamm, T., Zwerina, J., Klaus Klaushofer, A., & Kocijan, R. (2019) · Calcified Tissue International · doi:10.1007/s00223-019-00611-3 · Cited by 33
Rodríguez, A. J., Ernst, M., Nybo, M., Prieto‐Alhambra, D., Ebeling, P. R., Hermann, A. P., & Abrahamsen, B. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa481 · Cited by 36
Javaid, M. K. (2021) · Aging Clinical and Experimental Research · doi:10.1007/s40520-021-01844-9 · Cited by 37
Kim, H. Y. (2021) · Endocrinology and Metabolism · doi:10.3803/enm.2021.1170 · Cited by 34
“According to AAOMS and other groups [7,24], 4 years is suggested as the cutoff for low-dose BP treatment; however, in recent reviews, 3 years has been proposed as a cutoff based on studies reporting an early occurrence of zoledronate- and denosumab-associated ARONJs [29,58].”
BackgroundRiancho, J. A., Peris, P., González-Macías, J., & Pérez‐Castrillón, J. L. (2022) · Revista Clínica Española · doi:10.1016/j.rce.2021.12.007 · Cited by 35
Prieto‐Alhambra, D., Judge, A., Arden, N. K., Cooper, C. C., Lyles, K. W., & Javaid, M. K. (2013) · Osteoporosis International · doi:10.1007/s00198-013-2420-8 · Cited by 33
“The advent of parenteral therapies therefore represented a major therapeutic advance in the field [6].”
BackgroundSelection of antiresorptive or anabolic treatments for postmenopausal osteoporosis
Papapoulos, S. E., & Makras, P. (2008) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0941 · Cited by 39
“These inter-related actions reduce the risk of osteoporotic fractures, as shown in randomized, controlled trials and meta-analyses”
BackgroundPrevention of osteoporosis-related fractures among postmenopausal women and older men
Rahmani, P., & Morin, S. N. (2009) · Canadian Medical Association Journal · doi:10.1503/cmaj.080709 · Cited by 40
“Flu-like symptoms, reported in up to 10% of patients following infusion of zoledronic acid, are most prominent after the initial dose and are usually selflimited.(51) In one trial, the incidence of atrial fibrillation was reported to be higher among the participants given zoledronic acid than among those given placebo…”
BackgroundInfluentialBlake, G. M., Siddique, M. M., Frost, M. L., Moore, A. E. B., & Fogelman, I. (2011) · Bone · doi:10.1016/j.bone.2011.05.031 · Cited by 32
“Many treatments for osteoporosis and Paget's disease have a profound effect on bone remodelling [8–13], and studies of bone metabolism have an important role in the evaluation of their effect on bone tissue [14].”
BackgroundDanila, M. I., Outman, R. C., Rahn, E. J., Mudano, A. S., Redden, D. T., Li, P., Allison, J. J., Anderson, F. A., Wyman, A. S., Greenspan, S. L., et al. (2018) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3395 · Cited by 32
“The intervention included three components: (1) an introduction video explaining the reason for receiving the materials; (2) personalized videos addressing barriers to osteoporosis therapy or presenting general osteoporosis information (for those who did not rank barriers to treatment); and (3) a video on “how to comm…”
BackgroundAitken, D. A., Laslett, L. L., Cai, G., Hill, C. L., MARCH, L. M., Wluka, A. E., Wang, Y., Blizzard, L., Cicuttini, F., & Jones, G. (2018) · BMC Musculoskeletal Disorders · doi:10.1186/s12891-018-2143-2 · Cited by 32
Misof, B. M., Patsch, J., Roschger, P., Muschitz, C., Gamsjaeger, S., Paschalis, E. P., Prokop, E., Klaushofer, K., Pietschmann, P., & Resch, H. (2013) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2035 · Cited by 33
Zhao, X., Xu, X., Guo, L., Ragaz, J., Guo, H., Wu, J., Shao, Z., Zhu, J. Y., Guo, X., Chen, J., et al. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1183-6 · Cited by 31
“Several dosing schedules of zoledronic acid for the treatment of osteoporosis and bone metastases have been proposed [19, 20].”
Randomized controlled trial of zoledronic acid for treatment of osteoporosis in women
Bai, H., Jing, D., Guo, A., & Yin, S. (2013) · Journal of International Medical Research · doi:10.1177/0300060513480917 · Cited by 36
“Similarly, it has been reported that an annual single 15-min infusion of 5mg ZOL significantly improved BMD over a 3-year period and was not associated with serious adverse events, compared with placebo.(23) Published data on the effects of ZOL in osteoporosis are, however, inconsistent.”
ResultCurrent Controversies in the Management of Myeloma Bone Disease
Silbermann, R. W., & Roodman, G. D. (2016) · Journal of Cellular Physiology · doi:10.1002/jcp.25351 · Cited by 33
“Individuals with smoldering MM should receive bisphosphonates in doses used in patients with osteoporosis (5mg annual dosing of zoledronic acid) (Black et al., 2007), whereas patients with highrisk smoldering MM and bone loss should be treated with the same bisphosphonate schedules and doses used…”
BackgroundYuan, A., Munz, A., Reinert, S., & Hoefert, S. (2019) · Journal of Cranio-Maxillofacial Surgery · doi:10.1016/j.jcms.2019.06.004 · Cited by 33
Osteonecrosis de los maxilares: Documento de consenso
Henríquez, M. S., Romero, M. G. D. T., Jv, B. S., Díaz Curiel, M., Díez Pérez, A., Jódar Gimeno, E., Junquera Gutiérrez, L., Del Pino Montes, J., Barrero, M. V., Científico, M. D. C., et al. (2009) · Revista de Osteoporosis y Metabolismo Mineral · Cited by 46
Odds ratio vs risk ratio in randomized controlled trials
Balasubramanian, H., Ananthan, A., Rao, S. C., & Patole, S. (2015) · Postgraduate Medicine · doi:10.1080/00325481.2015.1022494 · Cited by 34
“8 [49] 26 Fonseca 2007 24 125 43 125 0.”
Akehurst, R. L., Brereton, N. J., Ariely, R., Lusa, T., Groot, M. D., Foss, P., & Boonen, S. (2011) · Journal of Medical Economics · doi:10.3111/13696998.2010.545563 · Cited by 35
Self-citationSignificance of combination therapy of zoledronic acid and gemcitabine on pancreatic cancer
Zhao, M., Tominaga, Y., Ohuchida, K., Mizumoto, K., Cui, L., Kozono, S., Fujita, H., Maeyama, R., Toma, H., & Tanaka, M. (2011) · Cancer Science · doi:10.1111/j.1349-7006.2011.02113.x · Cited by 33
“Bisphosphonates (BPs) are currently the most important class of inhibitors of osteoclast-mediated bone resorption 8 and are used extensively for the treatment of skeletal diseases, such as Paget’s disease 9 , postmenopausal osteoporosis 10 and tumor-induced osteolysis 11 .”
Orthopaedics in 2020: Predictors of Musculoskeletal Need*
Dunbar, M., Howard, A., Bogoch, E. R., Parvizi, J., & Kreder, H. J. (2009) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.h.01521 · Cited by 34
Fragility fracture prevention: review from a Japanese perspective.
Hagino, H. (2012) · Europe PMC (PubMed Central) · Cited by 32
Takahashi, S., Iwase, T., Kohno, N., Ishikawa, T., Taguchi, T., Takahashi, M., Horiguchi, J., Nakamura, S., Hozumi, Y., Fukunaga, M., et al. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-1973-0 · Cited by 32
Villa, J. C., Gianakos, A. L., & Lane, J. M. (2015) · HSS Journal® The Musculoskeletal Journal of Hospital for Special Surgery · doi:10.1007/s11420-015-9469-1 · Cited by 38
“In addition, they have all demonstrated improved BMD in postmenopausal women [2, 5, 19, 29, 45].”
BackgroundInfluentialPrevention and treatment of bone fragility in cancer patient
Ottanelli, S. (2015) · Clinical cases in mineral and bone metabolism · doi:10.11138/ccmbm/2015.12.2.116 · Cited by 35
“In addition, previously had been detected in the group treated with zoledronic acid, increase in BMD and a trend to a loss of height that was less than those treated with placebo (89).”
ResultTsourdi, E. A., Makras, P., Rachner, T. D., Pοlyzos, S. A., Rauner, M., Mandanas, S., Hofbauer, L. C., & Anastasilakis, A. D. (2018) · Bone · doi:10.1016/j.bone.2018.10.001 · Cited by 29
Yang, Y. C., Luo, X., Yan, F., Jiang, Z., Li, Y., Fang, C., & Shen, J. (2015) · Skeletal Radiology · doi:10.1007/s00256-015-2200-y · Cited by 31
Deeks, E. D., & Perry, C. M. (2008) · Drugs & Aging · doi:10.2165/0002512-200825110-00007 · Cited by 31
Evaluation and Treatment of Osteoporosis
O’Connor, K. (2016) · Medical Clinics of North America · doi:10.1016/j.mcna.2016.03.016 · Cited by 42
Chandran, M. (2022) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-3997000000564 · Cited by 34
“Recombinant human parathyroid hormone (1-34) [teriparatide]”
BackgroundGani, L. U., Sritara, C., Blank, R. D., Chen, W., Gilmour, J., Dhaliwal, R., & Gill, R. S. (2023) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2023.101440 · Cited by 41
Vilaça, T., Schini, M., Lui, L., Ewing, S. K., Thompson, A. R., Vittinghoff, E., Bauer, D. C., Eastell, R., Black, D. M., & Bouxsein, M. (2024) · Journal of Bone and Mineral Research · doi:10.1093/jbmr/zjae126 · Cited by 37
“27,36,40 Whereas there is no established threshold to define the r 2 value from the meta-regression required to establish that a surrogate endpoint is valid, the literature suggests that an r 2 value > 0.65 is an appropriate target for the acceptability of a surrogate endpoint.”
BackgroundInfluentialSelf-citationNext-generation probiotics and engineered BEVs for precision therapeutics in osteoporosis
Wei, J., Ding, W., Song, K., Zhang, Y., Luo, Q., & Qi, C. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1581971 · Cited by 31
New developments in the treatment of osteoporosis
Eriksen, E. F., Halse, J., & Moen, M. H. (2012) · Acta Obstetricia Et Gynecologica Scandinavica · doi:10.1111/j.1600-0412.2012.01473.x · Cited by 35
“Intravenous bisphosphonates may cause fever in around 20% of patients after administration of the first dose, while the risk is negligible on subsequent administrations (2) Recently, the following two purported adverse effects to long-term bisphosphonate treatment have been reported and been subjected to significant s…”
BackgroundSelf-citationEmerging Therapies for Osteoporosis
McClung, M. R. (2015) · Endocrinology and Metabolism · doi:10.3803/enm.2015.30.4.429 · Cited by 30
Discrepancies in predicted fracture risk in elderly people
Bolland, M. J., Jackson, R., Gamble, G. D., & Grey, A. B. (2013) · BMJ · doi:10.1136/bmj.e8669 · Cited by 30
Zhang, J., Wang, R., Zhao, Y.-L., Sun, X., Zhao, H.-X., Tan, L., Chen, D., & Xu, H. (2012) · Asian Pacific Journal of Tropical Medicine · doi:10.1016/s1995-7645(12)60118-7 · Cited by 30
“Black 2007[15] The United State 36 3 889/3 879 73.”
Bone markers and osteoporosis therapy
Bandeira, F. A. F., Costa, A. G., Filho, M. A. S., Pimentel, L., Lima, L., & Bilezikian, J. P. (2014) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/0004-2730000003384 · Cited by 37
González-Macías, J., del Pino‐Montes, J., Olmos, J. M., & Nogués, X. (2015) · Revista Clínica Española (English Edition) · doi:10.1016/j.rceng.2015.08.005 · Cited by 48
Tanaka, S., Miyazaki, T., Uemura, Y., Miyakawa, N., Gorai, I., Nakamura, T., Fukunaga, M., Ohashi, Y., Ohta, H., Mori, S., et al. (2016) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-016-0768-5 · Cited by 30
Wang, G., Sui, L., Gai, P. Y., Li, G., Qi, X., & Jiang, X. (2017) · Bone and Joint Research · doi:10.1302/2046-3758.67.bjr-2016-0292.r1 · Cited by 33
Minodronate for the treatment of osteoporosis
Ohishi, T., & Matsuyama, Y. (2018) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s149236 · Cited by 33
“7%) in HORIZONPFT.(31,59) Considering the lower affinity of minodronate than that of zoledronate to hydroxyapatite, the efficacy of minodronate for hip fracture prevention is expected because of a possibly wider distribution of minodronate than that of zoledronate.”
Fontalis, A., Kenanidis, E. I., Kotronias, R. A., Papachristou, A., Anagnostis, P. G., Potoupnis, M. E., & Tsiridis, E. E. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1594772 · Cited by 33
“Alendronate [18,19] + + 47% 48%–51% 35mg70 mg weekly* (oral) Risedronate [19–21] + + 41% 30%–39% 150 mg monthly* (oral) 3 mg every three months* (intravenous) Ibandronate [17,19] + + 62% NS 5 mg daily* (oral) 35 mg weekly* (oral) 150mg monthly* (oral) Zoledronic acid [19,22] + + 70% 25% 5mg yearly* (intravenous) 5mg e…”
Bisphosphonates and mortality: confounding in observational studies?
Bergman, J., Nordström, A., Hommel, A., Kivipelto, M., & Nordström, P. (2019) · Osteoporosis International · doi:10.1007/s00198-019-05097-1 · Cited by 35
Bai, X., Gao, Y., Zhang, M., Chang, Y., Chen, K., Li, J., Zhang, J., Liang, Y., Kong, J., Wang, Y., et al. (2020) · Nanoscale · doi:10.1039/c9nr09698a · Cited by 32
Alessandro de, S. I. R. E., Lippi, L., Aprile, V., Calafiore, D., Folli, A., D’Abrosca, F., Moalli, S., Lucchi, M., Ammendolia, A., & Invernizzi, M. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12101626 · Cited by 33
“A study of an extension of the treatment to 9 years showed that the bone mass values at the femoral level remained stable [158].”
BackgroundSeeto, A. H., Tadrous, M., Gebre, A. K., Lewis, J. R., Fink, H. A., Ebeling, P. R., & Rodríguez, A. J. (2022) · Bone · doi:10.1016/j.bone.2022.116610 · Cited by 32
Zoledronic acid and atrial fibrillation in cancer patients
Arslan, Ç., Aksoy, S., Dızdar, Ö., Dede, D. Ş., Harputluoğlu, H., & Altundağ, K. (2010) · Supportive Care in Cancer · doi:10.1007/s00520-010-0868-z · Cited by 29
“Treatment with a bisphosphonate was found to be associated with a significantly increased risk for atrial fibrillation (AF) in a few studies [1, 2]. Treatment of osteoporosis in postmenopausal women with once-yearly infusions of intravenous zoledronic acid (ZA) significantly increased serious AF [ 3 ].”
BackgroundMethodInfluentialAdherence with bisphosphonate therapy in US veterans with rheumatoid arthritis
Richards, J. S., Cannon, G. W., Hayden, C. L., AMDUR, R. L., Lazaro, D. M., Mikuls, T. R., Reimold, A. M., Caplan, L., Johnson, D. S., Schwab, P., et al. (2012) · Arthritis Care & Research · doi:10.1002/acr.21777 · Cited by 31
Wilczek, M. L., Kälvesten, J., Algulin, J., Beiki, O., & Brismar, T. B. (2012) · European Radiology · doi:10.1007/s00330-012-2706-9 · Cited by 35
“5 plus at least two prevalent vertebral fractures [41].”
BackgroundEffects of denosumab on bone density, mass and strength in women with postmenopausal osteoporosis
Törring, O. (2015) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x15579189 · Cited by 32
Metadata
- Authors
- Black, D. M., Delmas, P. D., Eastell, R., Reid, I. R., Boonen, S., Cauley, J. A., Cosman, F., Lakatos, P., Leung, P. C., Man, Z., Mautalen, C., Mesenbrink, P., Hu, H., Caminis, J., Tong, K., Rosario-Jansen, T., Krasnow, J., Hue, T. F., Sellmeyer, D., Eriksen, E. F., & Cummings, S. R.
- Affiliations
- University of California, San Francisco (US)
- Lyon 1 Université (FR)
- University of Sheffield (GB)
- University of Auckland (NZ)
- KU Leuven (BE)
- University of Pittsburgh (US)
- Helen Hayes Hospital (US)
- Semmelweis University (HU)
- Chinese University of Hong Kong (HK)
- Novartis (Switzerland) (CH)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-05-03
- Volume
- 356
- Issue
- 18
- Pages
- 1809-1822
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1993035292
- Cited by
- 2,986
- References
- 34
- Citations by year
- 2026: 90 · 2025: 120 · 2024: 107 · 2023: 96 · 2022: 114 · 2021: 140 · 2020: 127 · 2019: 124 · 2018: 127 · 2017: 121 · 2016: 150 · 2015: 154 · 2014: 154 · 2013: 194 · 2012: 174
- FWCI
- 258.58
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- IRIS (submittedVersion)
- ResearchSpace (University of Auckland) (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Funders
- National Institutes of Health (UL1TR000005)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Keywords
- zoledronic acid, postmenopausal osteoporosis, bisphosphonates, fracture risk reduction, vertebral fractures, hip fracture, bone mineral density, bone turnover markers, atrial fibrillation, renal function
- MeSH terms
- Zoledronic Acid, Aged, Aged, 80 and over, Atrial Fibrillation, Diphosphonates, Double-Blind Method, Drug Administration Schedule, Female, Hip Fractures, Humans, Imidazoles, Infusions, Intravenous, Risk, Biomarkers, Bone Density, Osteoporosis, Postmenopausal, Incidence, Spinal Fractures, Bone Density Conservation Agents, Fractures, Bone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.